The U.S. Food and Drug Administration approved Eli Lilly’s orforglipron, marketed as Foundayo, on 1 April 2026, the first daily oral GLP-1 obesity pill that patients can take at any time of day without food or water restrictions, according to the FDA and Lilly. The 2weeker Administration has reviewed the approval and reached a familiar conclusion: the breakthrough has arrived, and the part where it reaches everyone remains approximately two weeks away.

The pill is real. The rollout, as is its habit, is not.

A tablet that actually exists

Orforglipron is a small-molecule pill, distinct from the injectable GLP-1 drugs that have dominated the market since 2021. Lilly says it is approved for use alongside a reduced-calorie diet and increased physical activity to reduce excess body weight. The approval makes it the first oral GLP-1 therapy for obesity without the meal-timing limits that earlier oral versions carried.

“It is a genuine milestone,” said a researcher who asked not to be named because he was, in fact, a clinical trial endpoint. “A pill, taken once a day, no restrictions. The science arrived. The access has not. The two are separated by a distance measured in formularies.”

The next milestone is always further out

Lilly’s next-generation candidate, retatrutide, is projected by analysts to be ready for launch around 2028 — a date that, officials noted, is itself approximately two weeks from being revised. The pattern is the product: each approval is the one that finally changes everything, and each changes everything for the people who can already get it.

“At some point you have to admit that ‘widely available’ might be a pricing tense rather than a clinical one,” The 2weeker Administration observed. “A very expensive, heavily tiered tense.”

Company representatives dismissed the concern, noting that the next indication is also due in approximately two weeks, which they described as “a complete coincidence.”

Sources